Avadel Pharmaceuticals PLC (AVDL NASDAQ) stock market data APIs
$18.8899
0.01(0.1%)
as of November 6, 2025
Try our APIs with
free plan!
Avadel Pharmaceuticals PLC Financial Data Overview
Price chart is built with
Anychart
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Prev. Close
18.8899
Open
18.8991
High
19.0656
Low
18.8899
52 wk Range
6.38-19.06
Market Cap
1 827 M
P/E Ratio
0
Shares Outstanding
97 657 K
Revenue
249 M
EPS
0
Beta
1.632
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Avadel Pharmaceuticals PLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Avadel Pharmaceuticals PLC data using free add-ons & libraries
Get Avadel Pharmaceuticals PLC Fundamental Data
Avadel Pharmaceuticals PLC Fundamental data includes:
- Net Revenue: 249 M
- EBITDA: 8 199 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 0.0763
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Avadel Pharmaceuticals PLC News
New
FORM 8.1(a) & (b) (Opening Position Disclosure)
DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS): IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 20...
New Strong Sell Stocks for Nov. 5
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Avadel Pharmaceuticals plc AVDL is a biopharmaceutical company which provides passenger and cargo air transportation service...
Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Avadel Pharmaceuticals plc – Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September ...
What Jazz Pharmaceuticals (JAZZ)'s Cross-Licensing Settlement With Avadel Means For Shareholder Value
Jazz Pharmaceuticals plc recently resolved all ongoing litigation with Avadel Pharmaceuticals, establishing a global cross-licensing and royalty agreement involving their sleep disorder treatments and...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
